CR20240300A - Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos. - Google Patents

Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.

Info

Publication number
CR20240300A
CR20240300A CR20240300A CR20240300A CR20240300A CR 20240300 A CR20240300 A CR 20240300A CR 20240300 A CR20240300 A CR 20240300A CR 20240300 A CR20240300 A CR 20240300A CR 20240300 A CR20240300 A CR 20240300A
Authority
CR
Costa Rica
Prior art keywords
spirocyclic
inhibitors
complement factor
piperidinyl derivatives
piperidinyl
Prior art date
Application number
CR20240300A
Other languages
English (en)
Inventor
Stefanie Flohr
Nancy Labbe-Giguere
Anna Vulpetti
François Gessier
Michael Christoph Hediger
Konstanze Hurth
Christopher M Adams
Angela Vitrey
Lara C Czabaniuk
Tajesh Patel
Oliver Simic
Fabio Lima
Martin Sendzik
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20240300A publication Critical patent/CR20240300A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos de la fórmula (I) y composiciones farmacéuticas de los mismos de utilidad en el tratamiento de enfermedades o trastornos mediados por el factor B del complemento. (I)
CR20240300A 2022-01-24 2023-01-20 Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos. CR20240300A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263302246P 2022-01-24 2022-01-24
PCT/IB2023/050504 WO2023139534A1 (en) 2022-01-24 2023-01-20 Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CR20240300A true CR20240300A (es) 2024-08-23

Family

ID=85150566

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240300A CR20240300A (es) 2022-01-24 2023-01-20 Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.

Country Status (16)

Country Link
US (1) US20250115572A1 (es)
EP (1) EP4469157A1 (es)
JP (1) JP2025504859A (es)
KR (1) KR20240138095A (es)
CN (1) CN118696035A (es)
AU (1) AU2023209631A1 (es)
CA (1) CA3247772A1 (es)
CL (1) CL2024002205A1 (es)
CO (1) CO2024009660A2 (es)
CR (1) CR20240300A (es)
DO (1) DOP2024000142A (es)
IL (1) IL314186A (es)
JO (1) JOP20240165A1 (es)
MX (1) MX2024009062A (es)
PE (1) PE20242005A1 (es)
WO (1) WO2023139534A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4423076A4 (en) * 2021-10-27 2026-01-07 Hansoh Bio Llc PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES
WO2024049977A1 (en) * 2022-08-31 2024-03-07 Chinook Therapeutics, Inc. Substituted indole compounds and methods of use thereof
KR20250107882A (ko) * 2022-11-14 2025-07-14 노파르티스 파르마 아게 보체 인자 b 억제제의 고체 형태
WO2024222852A1 (zh) * 2023-04-27 2024-10-31 上海翰森生物医药科技有限公司 一种哌啶基吲哚化合物的盐及其制备方法
WO2025008451A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
AU2024290587A1 (en) 2023-07-04 2026-02-19 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
EP4739667A2 (en) 2023-07-06 2026-05-13 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
WO2025037010A1 (en) * 2023-08-16 2025-02-20 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
TW202543599A (zh) * 2024-03-08 2025-11-16 大陸商江蘇豪森藥業集團有限公司 一種多元螺環化合物的晶型、其製備方法和醫藥用途
WO2025256600A1 (zh) * 2024-06-12 2025-12-18 润尔眼科药物（广州）有限公司 一种杂环化合物及其用途
WO2026002007A1 (zh) * 2024-06-25 2026-01-02 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
BR112020003737A2 (pt) * 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
US20230286947A1 (en) * 2020-08-07 2023-09-14 Shanghai Meiyue Biotech Development Co. Ltd Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof
MX2023014274A (es) * 2021-06-03 2024-04-22 Chinook Therapeutics Inc Compuestos indol sustituidos y metodos de uso de los mismos.
CA3229360A1 (en) * 2021-08-18 2023-02-23 Chen Zhang Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
EP4423076A4 (en) * 2021-10-27 2026-01-07 Hansoh Bio Llc PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES

Also Published As

Publication number Publication date
WO2023139534A1 (en) 2023-07-27
DOP2024000142A (es) 2024-08-30
JP2025504859A (ja) 2025-02-19
AU2023209631A1 (en) 2024-07-25
KR20240138095A (ko) 2024-09-20
CO2024009660A2 (es) 2024-07-29
IL314186A (en) 2024-09-01
PE20242005A1 (es) 2024-10-03
CL2024002205A1 (es) 2025-01-10
CA3247772A1 (en) 2023-07-27
US20250115572A1 (en) 2025-04-10
CN118696035A (zh) 2024-09-24
EP4469157A1 (en) 2024-12-04
JOP20240165A1 (ar) 2024-07-24
MX2024009062A (es) 2024-07-29

Similar Documents

Publication Publication Date Title
DOP2024000142A (es) Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos
UY40204A (es) Inhibidores del Factor B del Complemento y Usos de los mismos
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
ECSP22061711A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
AR132802A1 (es) 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
DOP2026000079A (es) Inhibidores del factor b del complemento y usos de los mismos
CL2020001501A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
AR123685A1 (es) Antagonistas del mrgx2
CL2021000329A1 (es) Compuestos útiles en terapia del vih
CL2017001984A1 (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)
MX2025010920A (es) Compuestos quimicos
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2018002784A1 (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue.
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2023000670A1 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
MX2017016370A (es) Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
AR132698A1 (es) DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN)
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
CO2025001849A2 (es) Compuestos de imidazopiridina, preparación de los mismos y usos terapéuticos de los mismos
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4